The estimated Net Worth of Daniel D Shoemaker is at least $7.57 Million dollars as of 8 March 2021. Daniel Shoemaker owns over 25,000 units of Fate Therapeutics Inc stock worth over $283,318 and over the last 11 years he sold FATE stock worth over $4,464,067. In addition, he makes $2,818,590 as Chief Scientific Officer at Fate Therapeutics Inc.
Sign up
Daniel Shoemaker FATE stock SEC Form 4 insiders trading
Daniel has made over 10 trades of the Fate Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of FATE stock worth $2,043,500 on 8 March 2021.
The largest trade he's ever made was selling 25,000 units of Fate Therapeutics Inc stock on 8 March 2021 worth over $2,043,500. On average, Daniel trades about 7,443 units every 127 days since 2014. As of 8 March 2021 he still owns at least 73,020 units of Fate Therapeutics Inc stock.
You can see the complete history of Daniel Shoemaker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Shoemaker biography
Dr. Daniel D. Shoemaker Ph.D. is the Chief Scientific Officer of Fate Therapeutics Inc. He previously served as our Chief Research Officer from January 2015 to May 2015, and as our Chief Technology officer from February 2009 to January 2015. From 2003 to 2009, Dr. Shoemaker was Chief Scientific Officer of ICxBiosystems, a biotechnology firm that develops advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. From 1998 to 2003, Dr. Shoemaker held several positions at Merck Research Laboratories, including Director of Target Discovery, Senior Director at Rosetta Inpharmatics and research fellow in the Department of Molecular Neurosciences, where his main focus was on target identification and biomarker discovery. Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from the University of California, Santa Barbara.
What is the salary of Daniel Shoemaker?
As the Chief Scientific Officer of Fate Therapeutics Inc, the total compensation of Daniel Shoemaker at Fate Therapeutics Inc is $2,818,590. There are 1 executives at Fate Therapeutics Inc getting paid more, with John Wolchko having the highest compensation of $10,721,000.
How old is Daniel Shoemaker?
Daniel Shoemaker is 52, he's been the Chief Scientific Officer of Fate Therapeutics Inc since 2015. There are 6 older and 10 younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.
What's Daniel Shoemaker's mailing address?
Daniel's mailing address filed with the SEC is 3535 General Atomics Ct #200, San Diego, CA 92121, USA.
Insiders trading at Fate Therapeutics Inc
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part..., and Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.
What does Fate Therapeutics Inc do?
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
What does Fate Therapeutics Inc's logo look like?
Complete history of Daniel Shoemaker stock trades at Fate Therapeutics Inc
Fate Therapeutics Inc executives and stock owners
Fate Therapeutics Inc executives and other stock owners filed with the SEC include:
-
John Wolchko,
President, Chief Executive Officer, Director -
Bahram Valamehr,
Chief Development Officer -
Cindy Tahl,
General Counsel and Corporate Secretary -
Daniel Shoemaker,
Chief Scientific Officer -
J. Scott Wolchko,
Founder, CEO, Pres & Director -
Dr. Bahram Valamehr Ph.D.,
Chief R&D Officer -
Cindy R. Tahl,
Gen. Counsel & Corp. Sec. -
Karin Jooss,
Independent Director -
Shefali Agarwal,
Director -
William Rastetter,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
John Mendlein,
Independent Vice Chairman of the Board -
Robert Epstein,
Independent Director -
Michael Lee,
Independent Director -
Edward Dulac,
Chief Financial Officer -
Robert Hershberg,
Director -
Renee Leck,
IR Contact Officer -
Yu-Waye Chu,
Vice President - Clinical Development -
Sarah Cooley,
Senior Vice President - Clinical Translation -
Dr. Mark Plavsic D.V.M., Ph.D.,
Chief Technical Officer -
Dr. Yu-Waye Chu M.D.,
Sr. VP of Clinical Devel. -
Jim Beitel M.B.A.,
Sr. VP of Corp. Devel. -
Dr. Wen Bo Wang,
Sr. VP of Technical Operations -
Edward J. Dulac III,
CFO & Principal Accounting Officer -
Mark J Enyedy,
Director -
Stewart Abbot,
Chief Development Officer -
Chris Storgard,
Chief Medical Officer -
Amir Nashat,
Director -
Brian T. Powl,
Chief Commercial Officer -
J Scott Wolchko,
President and CEO -
Group, Llc Green Jeremy Red...,
-
Pratik S Multani,
Chief Medical Officer -
Peter D Flynn,
See remarks -
Christian Weyer,
See remarks -
Venture Fund Vi Lparch Vent...,
-
Venture Partners Vii Lpovp ...,
-
Venture Management Co. V, L...,
-
Robert Nelsen,
Director -
Associates V Lpvenrock Part...,
-
Yuan Xu,
-
Mark Plavsic,
Chief Technical Officer -
Neelufar Mozaffarian,